Yung Shun Wen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 13, 2022 /PRNewswire/ Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and positive results.

Charles linPrnewswire alar pharmaceuticals incDalar pharmaceuticalsClinical opiate withdrawal scaleOpioid craving visual analog scaleYung shun wen

Rompre le cycle de la dépendance aux opioïdes : Alar présente les résultats intermédiaires positifs de la buprénorphine injectable à action prolongée (ALA-1000) chez les patients dépendants aux opioïdes

Rompre le cycle de la dépendance aux opioïdes : Alar présente les résultats intermédiaires positifs de la buprénorphine injectable à action prolongée (ALA-1000) chez les patients dépendants aux opioïdes
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLinks to related source alar pharmaceuticalsDalar pharmaceuticalsAlar pharmaceuticals incDalar pharmaceuticalsYung shun wenAmerican fdaD alar pharmaceuticalsPharmaceuticals incFollowing linksRelated source alar pharmaceuticalsOran to launch the new republicஒன்றுபட்டது மாநிலங்களில்அலார் மருந்துகள்அலார் மருந்துகள் இன்க்மருந்துகள் இன்க்